Strategic report Governance & remuneration Financial statements Investor information Our investor proposition GSK is a science-led global healthcare company that aims to deliver growth and improving returns to shareholders through the development of innovative pharmaceutical, vaccine and consumer healthcare products.
Three world-leading businesses Each has a broad range Pharmaceuticals Vaccines Consumer Healthcare of growth drivers and the global presence to access bn bn bn increasing demand for 14.2 3.7 6.0 healthcare.
2015 turnover 2015 turnover 2015 turnover Leadership in key The most comprehensive One of the world's therapeutic areas vaccines portfolio in the leading global Consumer including Respiratory industry Healthcare companies and HIV by retail sales Strong R&D Around 40 new innovation potential medicines and vaccines in our pipeline R&D underpins all b Vaccines Respiratory Rare diseases proled at R&D event our businesses with diseases research focused in % six core therapy areas.
80 of which we believe are potentially first-in-class 20 ImmunoHIV infectious Oncology inammation diseases Potential to le up to 20 assets by 2020 b GSK R&D event on 3 November 2015. bn bn efficient global 2.5 1 operating model 2015 adjusted free cash ow excluding in incremental annual cost c costs funded by divestments savings delivered in 2015 and We are focused on optimising our operations bn bn through restructuring, 6.7 3 investments and net proceeds from disposals in annual cost savings modernisation to d generated in 2015 expected by end of 2017 improve profitability and eciency.
bn 3.7 reduction in net debt in 2015 c Excluding legal payments and also non-core d 1.6 billion annual savings restructuring and integration costs and the initial achieved by 31 December 2015. tax payments on the sale of the Oncology business.
